Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination

Giedre Gefenaite, Margot Tacken, Jens Bos, Irina Stirbu-Wagner, Joke C. Korevaar, Ronald P. Stolk, Bert Wolters, Marc Bijl, Maarten J. Postma, Jan Wilschut, Kristin L. Nichol, Eelko Hak

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Introduction:Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.Methods:VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.Results:Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.Conclusions:Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.

Original languageEnglish (US)
Article numbere66125
JournalPloS one
Volume8
Issue number6
DOIs
StatePublished - Jun 20 2013

Fingerprint

Dive into the research topics of 'Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination'. Together they form a unique fingerprint.

Cite this